8 research outputs found
ΠΠ΅ΡΠΎΠ΄Ρ ΡΠΊΡΡΡΠ°ΠΊΠΎΡΠΏΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΡΠΎΠΊΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ° Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ². ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΡΡΠ°ΠΉ
Β Β Introduction. Malignant tumors dominate in the picture of disability and mortality worldwide. One of the most frequent and dangerous comorbid conditions is kidney injury. At the same time, the most unfavorable incidence of acute kidney injury is recorded in multiple myeloma, leukemia, lymphoma and kidney and/or liver cancer and malignant ovarian neoplasms. In this regard, of vital importance is the choice of tactics in the prevention of thrombosis and thromboembolic complications, as well as the individual approach to of the anticoagulant therapy regimen during renal replacement therapy sessions, depending on the underlying disease and the state of the hemostatic system.Β Β Aim. To evaluate the effect of calcium citrate veno-venous hemodiafi ltration sessions on the hemostatic system of a patient with progressive organ dysfunctions associated with malignant ovarian neoplasm.Β Β Materials and methods. The methodology involved literature review and a case study to assess the effect of veno-venous hemodiafi ltration on hemostasis.Β Β Results and discussion. The clinical case was assessed in terms of P-selectin (CD62), which characterizes platelet activation processes. It should be noted that in this patient, the expression of P-selectin increased with each session of renal replacement therapy, while the platelet aggregation values remained at the level of the lower thresholds, which indicates a low probability of coagulation initiation. However, due to aggressive regulation of ovarian cancer by the hemostatic system in the form of production of inflammatory mediators, microvesicles, tissue factor expression and endothelial activation, attention should be paid to the molecular aspects of platelet activation in renal replacement therapy with regional citrate coagulation.Β Β Conclusion. The widespread use of extracorporeal detoxification methods is an independent risk factor not only for bleeding events, but may potentially contribute to thrombosis and thromboembolic complications, which requires a further detailed study of molecular mechanisms of hemostasis regulation by tumor and clinical evaluation of various anticoagulation methods.Β Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π½ΠΈΠΌΠ°ΡΡ Π»ΠΈΠ΄ΠΈΡΡΡΡΡΡ ΠΏΠΎΠ·ΠΈΡΠΈΡ Π² ΠΎΠ±ΡΠ΅ΠΉ ΡΡΡΡΠΊΡΡΡΠ΅ ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π½ΠΎΡΡΠΈ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΡ
ΠΈ Π³ΡΠΎΠ·Π½ΡΡ
ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠΈΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ΅ΠΊ. ΠΡΠΈ ΡΡΠΎΠΌ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½Π°Ρ ΡΠ°ΡΡΠΎΡΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΡΠ΅ΠΊ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΠ΅ΡΡΡ ΠΏΡΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠΈΠ΅Π»ΠΎΠΌΠ΅, Π»Π΅ΠΉΠΊΠ΅ΠΌΠΈΠΈ, Π»ΠΈΠΌΡΠΎΠΌΠ΅ ΠΈ ΡΠ°ΠΊΠ΅ ΠΏΠΎΡΠΊΠΈ ΠΈ / ΠΈΠ»ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΡ
ΡΠΈΡΠ½ΠΈΠΊΠΎΠ². Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ ΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎ Π²Π°ΠΆΠ½ΡΠΌ ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡΡ Π²ΡΠ±ΠΎΡ ΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΏΡΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² ΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Π±ΠΎΡΠ° ΡΠ΅ΠΆΠΈΠΌΠ° Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ ΡΠ΅Π°Π½ΡΠ°Ρ
ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°.Β Β Π¦Π΅Π»ΡΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡΠ΅Π½ΠΊΠ° Π²Π»ΠΈΡΠ½ΠΈΡ ΡΠ΅Π°Π½ΡΠΎΠ² ΠΊΠ°Π»ΡΡΠΈΠΉ-ΡΠΈΡΡΠ°ΡΠ½ΠΎΠΉ Π²Π΅Π½ΠΎ-Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ°ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΎΡΠ³Π°Π½Π½ΡΡ
Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΉ, ΡΠ°Π·Π²ΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° ΡΠΎΠ½Π΅ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ².Β Β ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ½Π°Π»ΠΈΠ· Π΄ΠΎΡΡΡΠΏΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ Π²Π»ΠΈΡΠ½ΠΈΡ Π²Π΅Π½ΠΎ-Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ°ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°.Β Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ»ΡΡΠ°Π΅ ΠΌΡ ΠΎΡΠ΅Π½ΠΈΠ»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ P-ΡΠ΅Π»Π΅ΠΊΡΠΈΠ½Π° (CD62), ΠΊΠΎΡΠΎΡΡΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅Ρ ΠΏΡΠΎΡΠ΅ΡΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ². Π‘Π»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ ΠΊΠ°ΠΆΠ΄ΡΠΌ ΡΠ΅Π°Π½ΡΠΎΠΌ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π»Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π -ΡΠ΅Π»Π΅ΠΊΡΠΈΠ½Π°, ΠΏΡΠΈ ΡΡΠΎΠΌ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π°Π³ΡΠ΅Π³Π°ΡΠΈΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² ΠΎΡΡΠ°Π²Π°Π»ΠΈΡΡ Π½Π° ΡΡΠΎΠ²Π½Π΅ Π½ΠΈΠΆΠ½ΠΈΡ
ΠΏΠΎΡΠΎΠ³ΠΎΠ²ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π½ΠΈΠ·ΠΊΠΎΠΉ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ ΠΈΠ½ΠΈΡΠΈΠ°ΡΠΈΠΈ ΡΠ²Π΅ΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ. ΠΠ΄Π½Π°ΠΊΠΎ, ΠΏΡΠΈΠ½ΠΈΠΌΠ°Ρ Π²ΠΎ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ°ΠΊΡ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠ° ΡΠΈΡΡΠ΅ΠΌΠΎΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° Π² Π²ΠΈΠ΄Π΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΠΌΠ΅Π΄ΠΈΠ°ΡΠΎΡΠΎΠ² Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ, ΠΌΠΈΠΊΡΠΎΠ²Π΅Π·ΠΈΠΊΡΠ», ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠΊΠ°Π½Π΅Π²ΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ, ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΎΠ±ΡΠ°ΡΠΈΡΡ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² ΠΏΡΠΈ ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ°ΡΠ½ΠΎΠΉ ΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠ΅ΠΉ.Β Β ΠΡΠ²ΠΎΠ΄Ρ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΡΠΈΡΠΎΠΊΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠΊΡΡΡΠ°ΠΊΠΎΡΠΏΠΎΡΠ°Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΡΠΎΠΊΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΠΉ, Π½ΠΎ ΠΌΠΎΠΆΠ΅Ρ ΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² ΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΡΡΠΎ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΎΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΈ
Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study
Background: The coronavirus disease-2019 (COVID-19) pandemic significantly affected management of cardiovascular disease around the world. The effect of the pandemic on volume of cardiovascular diagnostic procedures is not known. Objectives: This study sought to evaluate the effects of the early phase of the COVID-19 pandemic on cardiovascular diagnostic procedures and safety practices in Asia. Methods: The International Atomic Energy Agency conducted a worldwide survey to assess changes in cardiovascular procedure volume and safety practices caused by COVID-19. Testing volumes were reported for March 2020 and April 2020 and were compared to those from March 2019. Data from 180 centers across 33 Asian countries were grouped into 4 subregions for comparison. Results: Procedure volumes decreased by 47% from March 2019 to March 2020, showing recovery from March 2020 to April 2020 in Eastern Asia, particularly in China. The majority of centers cancelled outpatient activities and increased time per study. Practice changes included implementing physical distancing and restricting visitors. Although COVID testing was not commonly performed, it was conducted in one-third of facilities in Eastern Asia. The most severe reductions in procedure volumes were observed in lower-income countries, where volumes decreased 81% from March 2019 to April 2020. Conclusions: The COVID-19 pandemic in Asia caused significant reductions in cardiovascular diagnostic procedures, particularly in low-income countries. Further studies on effects of COVID-19 on cardiovascular outcomes and changes in care delivery are warranted
Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe
Objectives We aimed to explore the impact of the COVID-19 pandemic on cardiac diagnostic testing and practice and to assess its impact in different regions in Europe. Methods The online survey organised by the International Atomic Energy Agency Division of Human Health collected information on changes in cardiac imaging procedural volumes between March 2019 and March/April 2020. Data were collected from 909 centres in 108 countries. Results Centres in Northern and Southern Europe were more likely to cancel all outpatient activities compared with Western and Eastern Europe. There was a greater reduction in total procedure volumes in Europe compared with the rest of the world in March 2020 (45% vs 41%, p=0.003), with a more marked reduction in Southern Europe (58%), but by April 2020 this was similar in Europe and the rest of the world (69% vs 63%, p=0.261). Regional variations were apparent between imaging modalities, but the largest reductions were in Southern Europe for nearly all modalities. In March 2020, location in Southern Europe was the only independent predictor of the reduction in procedure volume. However, in April 2020, lower gross domestic product and higher COVID-19 deaths were the only independent predictors. Conclusion The first wave of the COVID-19 pandemic had a significant impact on care of patients with cardiac disease, with substantial regional variations in Europe. This has potential long-term implications for patients and plans are required to enable the diagnosis of non-COVID- 19 conditions during the ongoing pandemic
Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World
Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection